Here are the S-3 shelf registrations from Silo Pharma, Inc. (SILO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow SILO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SILO filings page.
Silo Pharma, Inc., a Nevada-based diversified developmental-stage biopharmaceutical and cryptocurrency company, has filed to register for resale up to 1,906,392 shares of common stock held by selling shareholders. The shares consist of 124,000 common shares issued in a July 2026 private placement and 1,782,392 shares issuable upon exercise of pre-funded, Series A-3, Series A-4 and placement agent warrants. This is a resale registration; the company will not receive proceeds from any sale of shares by selling holders.
The warrants are immediately exercisable at prices of $0.0001 (pre-funded), $6.21 (Series A-3 and A-4) and $8.065 (placement agent), with expirations ranging from 18 months to five years after effectiveness and subject to 4.99% or 9.99% beneficial ownership limits. If all 1,782,392 warrant shares registered here are exercised for cash, Silo estimates gross proceeds of approximately $8.07 million, intended for working capital and general corporate purposes. Assuming full cash exercise, common shares outstanding would be 3,035,002. Silo recently effected a 1-for-15 reverse stock split, reducing authorized common stock to 6,666,667 shares, and reported a 2025 net loss of $4,227,698 and a first-quarter 2026 net loss of $1,647,117. The company’s pipeline includes intranasal PTSD and Alzheimer’s candidates, a ketamine implant for fibromyalgia, and CNS peptide technology, alongside a crypto-asset treasury and staking strategy.